Intercept Pharmaceuticals (ICPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2017 | 12-2016 | 12-2015 | 12-2014 | 12-2013 | |
Sales | 130,956 | 24,951 | 2,782 | 1,742 | 1,622 |
Cost of Goods | 1,371 | N/A | N/A | N/A | N/A |
Gross Profit | 129,585 | 24,951 | 2,782 | 1,742 | 1,622 |
Operating Expenses | 465,568 | 427,489 | 231,938 | 114,912 | 41,074 |
Operating Income | -335,612 | -402,538 | -229,156 | -113,170 | -39,452 |
Interest Expense | 29,271 | 14,196 | 0 | 0 | 0 |
Other Income | 4,516 | 3,904 | 2,727 | -170,056 | -28,341 |
Pre-tax Income | -360,367 | -412,830 | -226,429 | -283,226 | -67,793 |
Net Income Continuous | -360,367 | -412,830 | -226,429 | -283,226 | -67,793 |
Net Income | $-360,367 | $-412,830 | $-226,429 | $-283,226 | $-67,793 |
EPS Basic Total Ops | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 |
EPS Basic Continuous Ops | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 |
EPS Diluted Total Ops | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 |
EPS Diluted Continuous Ops | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 |
EPS Diluted Before Non-Recurring Items | -14.38 | N/A | N/A | N/A | N/A |
EBITDA(a) | $-313,261 | $-386,841 | $-221,163 | $-109,361 | $-37,731 |